{"title":"Gradients of Nigrostriatal Iron Deposition in Healthy Aging and Synucleinopathies","authors":"Jiaqi Wen, Tao Guo, Xiaojie Duanmu, Chenqing Wu, Haoting Wu, Cheng Zhou, Qianshi Zheng, Weijin Yuan, Jianmei Qin, Zihao Zhu, Jingjing Wu, Jingwen Chen, Jingjing Xu, Yaping Yan, Jun Tian, Baorong Zhang, Hongjian He, Minming Zhang, Xiaojun Guan, Xiaojun Xu","doi":"10.1111/cns.70359","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>To investigate the gradients of nigrostriatal iron deposition in aging, Parkinson's disease (PD), and multiple system atrophy (MSA).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study included 100 young healthy controls, 171 old healthy controls (OHC), 231 PD, and 24 MSA patients. The brain iron content was quantified by quantitative susceptibility mapping. A spatial function method was employed to map the iron gradient along the principal axis of the subcortical structure. General linear models were used to compare differences in iron gradients between groups. Partial correlation was used to analyze the relationship between iron content and symptoms of synucleinopathies.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Nigrostriatal iron deposition in all gradient directions was observed during aging (<i>p</i> < 0.05). Compared to OHC, iron deposition was significant in nearly all substantia nigra (SN) segments in both PD and MSA (<i>p</i> < 0.05). MSA showed significant iron deposition in the posterolateral putamen compared to PD (<i>p</i> < 0.05). Iron deposition in the SN in PD and putamen in MSA correlated with disease severity.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Iron deposition in all gradient directions occurred in the nigrostriatal system during healthy aging, and this was more evident in the SN in both PD and MSA, with MSA displaying additional iron deposition in the posterolateral putamen.</p>\n </section>\n </div>","PeriodicalId":154,"journal":{"name":"CNS Neuroscience & Therapeutics","volume":"31 3","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cns.70359","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Neuroscience & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cns.70359","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Aims
To investigate the gradients of nigrostriatal iron deposition in aging, Parkinson's disease (PD), and multiple system atrophy (MSA).
Methods
This study included 100 young healthy controls, 171 old healthy controls (OHC), 231 PD, and 24 MSA patients. The brain iron content was quantified by quantitative susceptibility mapping. A spatial function method was employed to map the iron gradient along the principal axis of the subcortical structure. General linear models were used to compare differences in iron gradients between groups. Partial correlation was used to analyze the relationship between iron content and symptoms of synucleinopathies.
Results
Nigrostriatal iron deposition in all gradient directions was observed during aging (p < 0.05). Compared to OHC, iron deposition was significant in nearly all substantia nigra (SN) segments in both PD and MSA (p < 0.05). MSA showed significant iron deposition in the posterolateral putamen compared to PD (p < 0.05). Iron deposition in the SN in PD and putamen in MSA correlated with disease severity.
Conclusion
Iron deposition in all gradient directions occurred in the nigrostriatal system during healthy aging, and this was more evident in the SN in both PD and MSA, with MSA displaying additional iron deposition in the posterolateral putamen.
期刊介绍:
CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, epilepsy, and drug abuse.